Publikace

Monografie

Feltl D., Cvek J.: Klinická radiobiologie. Tobiáš 2008. ISBN 9788073111038

Kapitoly v monografiích

Dušek L, Vyzula R, Feltl D, Hajdúch M, Fínek J, Suchý M, Mužík J, Pavlík T. Monitoring of the Results and Quality of Cancer Care in the Czech Republic. In Dušek L, et al. Czech Cancer Care in Numbers. Grada 2010. ISBN 978-80-247-3244-2.
Zoul Z, Kubeš J, Cvek J: Hypertermie. In Petera J, Šlampa P: Radiační onkologie. Galén 2006. ISBN 8072624690.
Feltl D, Doležalová H, Šlampa P, Macháňová M. Lymfomy. In Petera J, Šlampa P: Radiační onkologie. Galén 2006. ISBN 8072624690.
Feltl D, Doležalová H, Šlampa P, Macháňová M. Plazmocytom. In Petera J, Šlampa P: Radiační onkologie. Galén 2006. ISBN 8072624690.

Impaktované publikace

Robertson JF, Llombart-Cussac A, Rolski J, Feltl D, Dewar J, Macpherson E, Lindemann J, Ellis MJ.Activity of fulvestrant 500 mg versus anastrozole 1 mg as first-line treatment for advanced breast cancer: results from the FIRST study. J Clin Oncol. 2009 Sep 20;27(27):4530-5.
Feltl D., Závadová E., Pála M., Hozák P.: The dynamics of plasma transforming growth factor beta 1 (TGF-ß1) level during radiotherapy with or without simultaneous chemotherapy in advanced head and neck cancer. Oral Oncology 2005;41:208-213.
Feltl D., Závadová E., Pála M., Hozák P. Posttreatment plasma transforming growth factor beta 1 (TGF-beta1) level predicts for late morbidity in patients with advanced head and neck cancer. Neoplasma 2005; 52(5):393-7.
Feltl D, Vošmik M, Jirásek M, Stáhalová V, Kubeš J. Symptomatic osteoradionecrosis of pelvic bones in patients with gynecological malignancies - result of a long-term follow-up. Int J Gynecol Cancer 2006;16:478–483.
Feltl D, Vítek P, Zámečník J. Hodgkin's lymphoma in the elderly: The results of 10 years of follow-up. Leukemia and Lymphoma 2006;47(8):1518-1522.
Feltl D, Marková J, Mociková H, Dědečková K, Kozák T. Prognostic impact of bone involvement in Hodgkin lymphoma. Neoplasma 2008; 55(2):96-100.
Halámka M, Cvek J, Kubeš J, Závadová E, Komínek P, Horáček J, and Feltl D. Plasma levels of vascular endothelial growth factor during and after radiotherapy in combination with celecoxib in patients with advanced head and neck cancer. Oral Oncology 2011;47:763-767.
Baumann M, Herrmann T, Koch R, Matthiessen W, Appold S, Wahlers B, Kepka L, Marschke G, Feltl D, Fietkau R, Budach V, Dunst J, Dziadziuszko R, Krause M, Zips D; on behalf of the CHARTWEL-Bronchus studygroup. Final results of the randomized phase III CHARTWEL-trial (ARO 97-1) comparing hyperfractionated-accelerated versus conventionally fractionated radiotherapy in non-small cell lung cancer (NSCLC). Radiother Oncol. 2011;100:76-85.
Kubeš J, Cvek J, Vondráček V, Pála M, Feltl D. Accelerated radiotherapy with concomitant boost technique (69.5 Gy/5 weeks). An alternative in the treatment of locally advanced head and neck cancer. Strahlenther Okol 2011;87(10):651-655.

Publikace v impaktovaných sbornících

Feltl D., Vítek P.: In-field relapse in mantle-irradiated patients with Hodgkin’s disease. European Journal of Cancer 1998;34: Suppl.2, S25.
Feltl D., Vítek P., Zámečník J.: Twenty years experience with treatment of elderly patients with Hodgkin’s disease . Leukemia and Lymphoma 2001;42: Suppl.2, 84.
Feltl D., Vošmik M., Jirásek M., Stáhalová V.: Osteoradionecrosis of pelvic bones – a single institution experience. European Journal of Cancer 2001;37: Suppl.6, S199.
Feltl D., Vošmik M., Jirásek M., Stáhalová V., Závadová E.: Can we predict the late effects after radiotherapy of cervical cancer? Radiotherapy and Oncology 2002;64,Suppl.1, S34.
Zámečník J., Vítek P., Feltl D., Stáhalová V., Vošmik M.: Second primaries in patients with Hodgkin’s disease. Radiotherapy and Oncology 2002;64,Suppl.1, S170.
Dědečková K., Feltl D., Pála M., Vošmik M., Veselý J., Frencl L., Homola L., Kvěch J.: The three-field technique used in irradiation of cervical lymph node system in patients with advanced head and neck cancer. Radiotherapy and Oncology 2002;64,Suppl.1, S231.
Marková J., Feltl D., Vajchrová M., Kozák T.: Low relapse rate of Hodgkin’s lymphoma in patients treated according to the strategy of the German Hodgkin’s Lymphoma Study Group (GHSG). Onkologie – International Journal for Cancer Research and Treatment, 2002;25(Sonderheft 4):195.
Marková J., Král Z., Feltl D., Kozák T., Vorlíček Z: Low relapse rate of Hodgkin’s lymphoma in patients treated according to the strategy of the German Hodgkin’s lymphoma study group in the Czech Republic. Blood 2002;100, Suppl.1, 292b.
Móciková H., Feltl D., Kozák T., Marková J.: Thyroid diseases after therapy for Hodgkin’s lymphoma. Onkologie – International Journal for Cancer Research and Treatment, 2003;26(Sonderheft 5):187.
Marková J., Móciková H., Feltl D., Kozák T.: Thyroid diseases after therapy for Hodgkin’s lymphoma. Blood 2003; 102(11): 315.
Feltl D., Marková J., Mociková H., Kozák T.: Predictive power of bone involvement in Hodgkin’s lymphoma. Eur J Haematol 2004;73 (Suppl. 65): 47.
Mociková H., Marková J., Bělohlávek O., Čermák F., Čáp F., Feltl D., Kozák T.: Comparison between conventional imaging methods and positron emission tomography in the treatment of Hodgkin’s lymphoma. Eur J Haematol 2004;73 (Suppl. 65): 32.
> Marková J., Zídka M., Feltl D., Mociková H., Kozák T.: Osteonecrosis as a complication of treating Hodgkin’s lymphoma after BEACOPP chemotherapy. Eur J Haematol 2004;73 (Suppl. 65): 23.
Feltl D., Závadová E., Pála M., Hozák P.: Posttreatment plasma TGF-beta1 level predicts late morbidity in advanced head and neck cancer. Int J Rad Oncol Biol Phys 2004;60(Suppl.1):S516.
Marková J., Zídka M., Feltl D., Mociková H., Kozák T.: Osteonecrosis as a complication of treating Hodgkin’s lymphoma after BEACOPP chemotherapy. Onkologie – International Journal for Cancer Research and Treatment, 2004;27(Suppl 3):P603.
Móciková H., Marková J., Bělohlávek O., Čáp F., Čermák F., Feltl D., Kozák T.: A Comparison Between Conventional Imaging Methods and Positron Emission Tomography in the Treatment of Hodgkin’s Lymphoma. Onkologie – International Journal for Cancer Research and Treatment, 2004;27(Suppl 3):O334.
Marková J, Zídka M, Feltl D, Móciková H, Kozák T. Osteonecrosis as a complication of treating Hodgkin’s lymphoma after BEACOPP chemotherapy. Annals of Oncology 2005;16(Suppl. 5):116.
Móciková H, Marková J, Bělohlávek O, Skopalová M, Čáp F, Čermák F, Feltl D, Kozák T. PET findings in lungs in patients treated for Hodgkin’s lymphoma. Annals of Oncology 2005;16(Suppl. 5):118.
Móciková H, Marková J, Bělohlávek O, Skopalová M, Čáp F, Čermák F, Feltl D, Kozák T. PET findings in lungs in patients treated for Hodgkin’s lymphoma. Onkologie – International Journal for Cancer Research and Treatment, 2005;28(suppl.3):153.
Marková J, Král Z, Móciková H, Feltl D, Klásková K, Šmardová L, Wagnerová B, Vorlíček J, Kozák T. 10 years of cooperation with the German Hodgkin Study Group (GHSG). Onkologie – International Journal for Cancer Research and Treatment, 2005;28(Suppl.3):270.
Baumann M, Hermann T, Koch R, Wahlers B, Kepka L, Marschke G, Feltl D, Fietkau R, Budach V, Dunst J. Continuous hyperfractionated accelerated radiotherapy - weekend less (CHARTWEL) versus conventionally fractionated (CF) radiotherapy in non-small-cell lung cancer (NSCLC): first results of a phase III randomised multicentre trial (ARO 971). European Journal of Cancer 2005;3(Suppl. 2):322.
Zavadova E , Chod J, Feltl D, Rob L, Fucikova T. Increased TGF-beta 1 plasma level correlates with the disease progression in cancer patients. European Journal of Clinical Investigation 2006;36 (s1), 14.
Feltl D, El-Lababidi N, Kindlová E, Šejdová M. High dose accelerated radiotherapy for inoperable squamous lung cancer – a phase II study. Lung cancer 2006;52(Suppl.1), 22.